SCHEMBL3524348

SCHEMBL3524348

O=C(O)CNC(=O)c1c(O)cc(-c2cccc([N+](=O)[O-])c2)c2nccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.47
PDE4A P27815 3/20 0.42
PDE4B Q07343 2/20 0.42
TOP1 P11387 1/20 0.42
EGLN1 Q9GZT9 7/20 0.40
FTO Q9C0B1 3/20 0.40
KDM6B O15054 2/20 0.40
HIF1AN Q9NWT6 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM3A Q9Y4C1 1/20 0.40
PDE4D Q08499 3/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
PDE4C Q08493 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HDAC2 Q92769 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
EGLN2 Q96KS0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524375 0.85 EGLN3 (0.57) EGLN3EGLN1FTOKDM6BHIF1AN
SCHEMBL3766884 0.81 EGLN3 (0.47) EGLN3EGLN1FTOKDM6BHIF1AN
SCHEMBL3519390 0.81 EGLN3 (0.69) EGLN3EGLN1FTOHIF1ANKDM5B
SCHEMBL3522844 0.80 EGLN3 (0.46) EGLN3EGLN1FTOEGLN2
SCHEMBL3519662 0.75 EGLN3 (0.46) EGLN3EGLN1FTOHIF1ANEGLN2
SCHEMBL3517879 0.75 EGLN3 (0.48) EGLN3EGLN1FTOEGLN2KDR
SCHEMBL3517314 0.75 EGLN3 (0.48) EGLN3EGLN1FTOKDM6BKDM5B
SCHEMBL3518850 0.73 EGLN3 (0.48) EGLN3EGLN1FTOEGLN2RAB9A
SCHEMBL3753830 0.73 EGLN3 (0.46) EGLN3EGLN1FTOEGLN2RAB9A
SCHEMBL3521981 0.72 EGLN1 (0.43) EGLN3EGLN1FTOKDM6BKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885PDE4A 1319/4885PDE4B 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.